Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 1823710, 6 pages
https://doi.org/10.1155/2018/1823710
Research Article

The Utility of 18F-FDG PET/CT for Monitoring Response and Predicting Prognosis after Glucocorticoids Therapy for Sarcoidosis

1Department of Respiratory Disease, Daping Hospital, Third Military Medical University, Chongqing 400042, China
2Department of Nuclear Medicine, Daping Hospital, Third Military Medical University, Chongqing 400042, China

Correspondence should be addressed to Rongbing Jin; moc.621@99brnij and Yong He; moc.621@8998gnoyeh

Received 30 October 2017; Revised 22 January 2018; Accepted 24 January 2018; Published 1 March 2018

Academic Editor: Gernot Zissel

Copyright © 2018 Hengyi Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive committee, February 1999,” American Journal of Respiratory and Critical Care Medicine, vol. 160, pp. 736–755, 1999.
  2. D. Valeyre, A. Prasse, H. Nunes, Y. Uzunhan, P.-Y. Brillet, and J. Müller-Quernheim, “Sarcoidosis,” The Lancet, vol. 383, no. 9923, pp. 1155–1167, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. R. L. M. Mostard, J. A. Verschakelen, M. J. P. G. Van Kroonenburgh et al., “Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis,” Respiratory Medicine, vol. 107, no. 3, pp. 439–447, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Biller, G. Zissel, B. Ruprecth, M. Nauck, A. Busse Grawitz, and J. Müller-Quernheim, “Genotype-corrected reference values for serum angiotensin-converting enzyme,” European Respiratory Journal, vol. 28, no. 6, pp. 1085–1090, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. R. G. Keijsers, J. C. Grutters, M. Thomeer et al., “Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET,” The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 55, pp. 66–71, 2011. View at Google Scholar
  6. J. J. Braun, R. Kessler, A. Constantinesco, and A. Imperiale, “18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 8, pp. 1537–1543, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Prager, M. Wehrschuetz, B. Bisail et al., “Comparison of 18F-FDG and 67Ga-citrate in sarcoidosis imaging,” Nuklearmedizin, vol. 47, no. 1, pp. 18–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Sobic-Saranovic, I. Grozdic, J. Videnovic-Ivanov et al., “The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis,” Journal of Nuclear Medicine, vol. 53, no. 10, pp. 1543–1549, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. R. L. Mostard, S. M. Van Kuijk, J. A. Verschakelen et al., “A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis,” BMC Pulmonary Medicine, vol. 12, article 57, 2012. View at Publisher · View at Google Scholar
  10. F. Jamar, J. Buscombe, A. Chiti et al., “EANM/SNMMI guideline for 18F-FDG use in inflammation and infection,” Journal of Nuclear Medicine, vol. 54, no. 4, pp. 647–658, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. A. S. Teirstein, J. Machac, O. Almeida, P. Lu, M. L. Padilla, and M. C. Iannuzzi, “Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis,” Chest, vol. 132, no. 6, pp. 1949–1953, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Carbone, D. Penna, R. Baughman, and E. Lower, “Accuracy of serial PET-CT imaging in systemic sarcoidosis,” Journal of Clinical Imaging Science, vol. 4, article 21, 2014. View at Google Scholar
  13. G. Treglia, S. Annunziata, D. Sobic-Saranovic, F. Bertagna, C. Caldarella, and L. Giovanella, “The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: An updated evidence-based review,” Academic Radiology, vol. 21, no. 5, pp. 675–684, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Valeyre, J. Bernaudin, Y. Uzunhan et al., “Clinical presentation of sarcoidosis and diagnostic work-up,” Seminars in Respiratory and Critical Care Medicine, vol. 35, no. 3, pp. 336–351, 2014. View at Publisher · View at Google Scholar
  15. J. Mañá and C. Gámez, “Molecular imaging in sarcoidosis,” Current Opinion in Pulmonary Medicine, vol. 17, no. 5, pp. 325–331, 2011. View at Publisher · View at Google Scholar
  16. M. A. Judson, “Advances in the diagnosis and treatment of sarcoidosis,” F1000Prime Reports, vol. 6, article 89, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Yamane, O. Daimaru, S. Ito et al., “Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas,” Journal of Nuclear Medicine, vol. 45, pp. 1838–1842, 2004. View at Google Scholar